Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07838194 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children

Name: Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children — clinical trial record (NCT07838194)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ZEBRHA 3

StatusNot Yet Recruiting

PhasePhase 3

SponsorHoffmann-La Roche

Started2026-11-30

View on ClinicalTrials.gov ↗

Roche/Genentech

364 trials monitored

See 34 trials at risk

Hemophilia

231 trials monitored

See 10 trials at risk

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of NXT007 prophylaxis in pediatric patients aged 0 to 11 years with severe or moderate congenital hemophilia A without factor VIII inhibitors or congenital hemophilia A of any severity (severe, moderate, and mild) with inhibitors (emicizumab-naïve and treated). Patients with hemophilia A aged ≥12 to \<18 years old with a body weight of \<40 kilograms (kg) are also able to participate.

Trial Details

NCT Number	NCT07838194
Lead Sponsor	Hoffmann-La Roche Collaborators: Chugai Pharmaceutical
Conditions	Hemophilia A
Enrollment	50 participants
Start Date	2026-11-30
Primary Completion	2028-09-30 (estimated)
Study Completion	2031-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-09-24